Klaus Strebhardt
Overview
Explore the profile of Klaus Strebhardt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
4124
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gasimli K, Raab M, Mandal R, Kramer A, Pena-Llopis S, Tahmasbi Rad M, et al.
Cancers (Basel)
. 2024 Jan;
16(1).
PMID: 38201534
Ovarian cancer is one of the most lethal gynecological cancers worldwide, with approximately 70% of cases diagnosed in advanced stages. This late diagnosis results from the absence of early warning...
2.
Raab M, Kostova I, Pena-Llopis S, Fietz D, Kressin M, Aberoumandi S, et al.
Cancer Commun (Lond)
. 2023 Dec;
44(1):101-126.
PMID: 38140698
Background: The cellular tumor protein p53 (TP53) is a tumor suppressor gene that is frequently mutated in human cancers. Among various cancer types, the very aggressive high-grade serous ovarian carcinoma...
3.
Raab M, Matthess Y, Raab C, Gutfreund N, Dotsch V, Becker S, et al.
Oncogene
. 2023 Jul;
42(34):2590.
PMID: 37488194
No abstract available.
4.
Rak M, Tesch R, Berger L, Shevchenko E, Raab M, Tjaden A, et al.
Eur J Med Chem
. 2023 Apr;
254:115347.
PMID: 37094449
Salt-inducible kinases 1-3 (SIK1-3) are key regulators of the LKB1-AMPK pathway and play an important role in cellular homeostasis. Dysregulation of any of the three isoforms has been associated with...
5.
Mandal R, Raab M, Rodel F, Kramer A, Kostova I, Pena-Llopis S, et al.
Cell Mol Life Sci
. 2023 Feb;
80(3):64.
PMID: 36807766
No abstract available.
6.
Fleischmann M, Mandal R, Kostova I, Raab M, Sanhaji M, Hehlgans S, et al.
Cancers (Basel)
. 2022 Nov;
14(22).
PMID: 36428594
Introduction: After primary platinum-based chemoradiation of locally advanced uterine cervical cancer, a substantial proportion of women present with persistent, recurrent or metastatic disease, indicating an unmet need for biomarker development....
7.
Mandal R, Raab M, Rodel F, Kramer A, Kostova I, Pena-Llopis S, et al.
Cell Mol Life Sci
. 2022 Nov;
79(12):597.
PMID: 36399280
Cervical cancer is the fourth most frequently diagnosed and fatal gynecological cancer. 15-61% of all cases metastasize and develop chemoresistance, reducing the 5-year survival of cervical cancer patients to as...
8.
Gasimli K, Raab M, Tahmasbi Rad M, Kurunci-Csacsko E, Becker S, Strebhardt K, et al.
Int J Mol Sci
. 2022 Sep;
23(18).
PMID: 36142803
Ovarian cancer (OC) accounts for approximately 4% of cancer deaths in women worldwide and is the deadliest gynecologic malignancy. High-grade serous ovarian cancer (HGSOC) is the most predominant ovarian cancer,...
9.
The Role of DAPK1 in the Cell Cycle Regulation of Cervical Cancer Cells and in Response to Topotecan
Gasimli K, Raab M, Becker S, Sanhaji M, Strebhardt K
J Cancer
. 2022 Feb;
13(3):728-743.
PMID: 35154442
Cervical cancer is one of the most serious health conditions, with nearly 500,000 women developing the disease each year worldwide. At present, the treatment of recurrent cervical cancer remains largely...
10.
Fleischmann M, Chatzikonstantinou G, Fokas E, Wichmann J, Christiansen H, Strebhardt K, et al.
Cancers (Basel)
. 2021 Nov;
13(22).
PMID: 34830902
Uterine cervical cancer is one of the leading causes of cancer-related mortality in women worldwide. Each year, over half a million new cases are estimated, resulting in more than 300,000...